arrow
M

Maxwell Sauder

University of Toronto
H指数:14
被引数:809

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

Rezpegaldesleukin治疗中重度特应性皮炎(REZOLVE-AD):一项国际性、双盲、安慰剂对照、随机期2b研究的16周诱导期最终结果

2026-08-220
PRE
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

奈莫珠单抗治疗结节性痒疹长达100周: 奥林匹亚LTE中期分析

2025-12-010
OAAI
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

增强型与标准皮肤管理联合阿曼曲妥珠单抗-拉泽替尼在EGFR突变型晚期NSCLC中的应用比较:COCOON全球随机对照试验

2025-09-090
OAAI
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance

免疫检查点抑制剂诱导的银屑病的系统性治疗:基于推断的指导

2025-07-210
OAAI
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

高度选择性的TYK2别构抑制,使用口服ESK-001治疗中度至重度斑块状银屑病:来自STRIDE研究的12周、随机、双盲、安慰剂对照、剂量探索的2期研究结果

2025-07-120
PRE
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients

定制ctDNA用于高危黑色素瘤患者分子残留疾病的纵向检测

2024-11-011
OAAI
Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process
2024-10-260
OA
A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
2024-08-080
PRE
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
LANCET
IF88.5
2024-08-013
PRE
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
2023-10-211
OAAI
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management
2023-05-193
OA